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Background: Non Muscle Invasive Bladder Transitional Cancer (NMIBC) and Muscle Invasive Bladder Transitional
Cancer (MIBC)/invasive have different gene profile and clinical course. NMIBC prognosis is not completely
predictable, since the relapse rate is higher than 20%, even in the form of MIBC. The aim of this study is to
evaluate if UTR expression can discriminate between NMIBC and MIBC and predict the risk of relapses in NMIBCs.
Methods: We have investigated upon urotensin-II (UII) receptor (UTR) expression in vivo in 159 patients affected by
NMIBC. The biological role of UTR was also investigated in vitro. UTR expression was evaluated in a tissue-micro-array,
consisting of normal, NMIBC and invasive bTCC samples.
Results: UTR discriminated between NMIBC and MIBC and showed a significant correlation between low UTR
expression and shorter disease free survival in NMIBC. The superagonist UPG84 induced growth suppression at nM
concentrations on 3/4 cell lines. Bladder cancer cell treatment with the antagonist urantide or the knock-down of UTR
with a specific shRNA significantly blocked both the motility and invasion of bladder cancer cells.
Conclusions: The evaluation of UTR expression can discriminate between NMIBC at high and low risk of relapse.
Moreover, our data suggest that UTR is involved in the regulation of motility, invasion and proliferation of bladder
cancer cells. High UTR expression is an independent prognostic factor of good prognosis for NMIBC regulating motility
and invasion of bladder cancer cells.
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Bladder transitional cell carcinoma (bTCC) represents the
4th most common malignancy in the world [1]. Tumors
not invading into muscularis propria, include non invasive
papillary TCC (pTa), carcinoma in situ (CIS) (pTis), and
tumors invading into lamina propria (pT1): “Non-Muscle
Invasive bladder transitional cancer” (NMIBC). Invasive
tumors infiltrate muscolaris propria: “Muscle-Invasive
bladder transitional cancer” (MIBC) [2,3]. NMIBC tumors
have a quite favourable clinical outcome while a high mor-
tality rate has been reported for invasive tumors. About* Correspondence: michele.caraglia@unina2.it
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unless otherwise stated.60% to 70% of NMIBC recur, and about 15% to 25% of pa-
tients relapse with invasive bladder cancer [4]. Histopatho-
logical stage and grade are currently the two most
important factors in determining behaviour and treatment
plan for bladder tumors [5]. Prognosis of NMIBC remains
unpredictable for both recurrence and progression.
Many biomarkers have been proposed and within them,
p53-dependent deregulated pathways seem to be strongly
associated to invading tumors [6]. Moreover, bTCC could
promote its growth and progression through autocrine/
paracrine regulator peptides, such as vascular endothelial
growth factor (VEGF) and proepithelin [7-11].
Recently, Urotensin-II receptor (UTR) has been detected
in several tumor cell lines but there are conflicting results
about its role in tumor progression [12,13].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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renocortical and renal cell carcinoma proliferation [14,15].
In lung adenocarcinoma, it has been demonstrated that
treatment with UTII, produced an increased tumor vol-
ume in vitro and in vivo [16].
Our group has recently demonstrated that UTR low
expression in prostate adenocarcinoma was significantly
associated to both shorter disease free survival (DFS)
and overall survival (OS) [12].
In this study, we evaluated UTR expression in a series
of bladder cancer cell lines and its involvement in the
regulation of biological functions like invasion and mo-
tility of bladder cancer cells.Methods
Bladder cancer TMA building
A progressive Tissue Micro-Array (TMA), has been
constructed using 130 tissue samples (113 tumour and
17 normal tissues), after pathologic re-evaluation accord-
ing WHO/ISUP 2007 [17].
Tumor tissues included 36 NMIBC and 77 MIBC. All
tumours and controls have been reviewed by two experi-
enced pathologists (RF, GB). Tissue cylinders were broughtFigure 1 Immunohistochemical UTR expression in a progressive Blad
UTR expression in MIBC (20x and 40x). E,F): negative UTR expression in invinto one recipient paraffin block using a semiautomated
tissue arrayer (Galileo TMA).
The bladder cancer samples were collected from the
National Institute of Tumours of Naples after Internal
Ethical Institutional approval in compliance with the
Helsinki DeclarationPatients and specimens of prognostic series of NMIBC
159 patients, undergone to bladder biopsy from 2000 to
2008 at the National Cancer Institute “Fondazione Giovanni
Pascale” of Naples have been included in this study.
84 (53%) of 159 patients showed relapses. All cases were
reviewed according to WHO classification criteria [17].
Medical records have been reviewed for clinical informa-
tion, including histologic parameters assessed on standard
H&E-stained slides.Immunohistochemistry analysis
Immunohistochemical staining was done on slides from
formalin-fixed, paraffin embedded tissues, to evaluate
UTR expression. After protein block, slides were incu-
bated with primary anti-UTR antibody followed by sec-
ondary antibody (Novocastra Streptavidin-HRP) andder TMA. A,B): High UTR expression in NMIBC (20x and 40x); C,D): low
asive tumor (20× and 40×).
Table 1 Clinical-pathological characteristics of the
Superficial TCC patients
UTR Low
expression
UTR High
expression
Patients without relapse (84) 38 46
Sex Male 28 37
Female 10 9
Grade High grade 11 8
Low grade 27 38
Infiltration No infiltration 26 35
Lamina propria 12 11
Patients with subsequent relapse (75) 56 19
Sex Male 47 13
Female 9 6
Grade High grade 16 6
Low grade 40 13
Infiltration No infiltration 34 11
Lamina propria 22 8
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were counterstained with hematoxylin and mounted.
RNA extraction and analysis
Total RNA was isolated from FFPE biopsies of prognostic
series whole section, collected in National Cancer Institute
“Fondazione G. Pascale” Institutional Bio-Bank, using High
pure FFPE RNA Micro Kit (Roche). RNA was subjected to
cDNA synthesis using the Ready To Go You-PrimerFigure 2 Immunohistochemical UTR expression in NMIBC. A, A1): High
UTR expression (20×, 40×) in a patient with recurrence.First-Strand Beads kit (Amersham Biosciences) in a re-
action mixture containing random hexamers (Applied
Biosystems).
Real-time PCR
Quantitative RT–PCR was performed in a LightCycler
system (Roche) using TaqMan® analysis. All reactions
were performed in triplicate. The thermal cycling condi-
tions included a step of 20 sec at 95°C followed by 40 -
cycles of 95°C for 1 sec and 60°C for 20 sec. Comparative
Ct method was used to determine human UTR gene vari-
ation, using as reference gene TaqMan Endogenous Con-
trols Human ACTB (β-actin) Endogenous Control
(RealTime Designer Assay, Roche). We identified a cali-
brator cell line (LNCaP) that represents the unitary
amount of the target, consequently the samples express
n-fold mRNA relative to the calibrator.
Statistical analysis
UTR immunohistochemistry expression was evaluated in
bladder cancer TMA including normal, NMIBC and inva-
sive samples. The mean and median tissue UTR expression,
expressed as a percentage of immunoreactive cells, was cal-
culated. Kruskal-Wallis test identified differences in median
expression values. Selection of the median value as cut-off
score was based on evaluation of the distribution of UTR
scores. Differences in the number of negative and positive
cases were analyzed using a test of equal proportions.
UTR expression was then evaluated on a prognostic series
of NMIBC with complete clinical-pathological information.UTR expression (20x, 40x) in a patient without recurrence; B, B1): low
Figure 3 Immunohistochemical UTR expression in a patient with no recurrence. A, B: High UTR expression (20×, 40×) in a patient who has
not developed a relapse; C, D: low UTR expression (20×, 40×).
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molecular and clinical-pathological parameters was
calculated using contingency table methods and tested
for significance using the Pearson chi-squared test.
Univariate and multivariate relative risks have been
calculated using the COX proportional hazards re-
gression. All calculations have been performed using
the SPSS (Statistical Package for the Social Science
rel.13) software (Chicago, IL) and the results have
been considered statistically significant when P-value
has been ≤ 0.05.Cell lines and cell proliferation by MTT assay
hUII and urantide, the agonist–antagonistic compounds
of UII, UPG83, UPG84 and UPG85 were all provided by
Prof. P. Grieco [18].Figure 4 Kaplan–Meier survival curve. A) Association between low UTR
grade and shorter time of relapse. C) Shorter disease-free survival is associaHT1376, MCR, T24 and RT112, cell lines of human
bladder cancer, were provided by ATCC. HT1376 and
T24 are a grade 3 whereas RT112 is a grade 2 urinary
bladder cell line. Cell lines were plated in 96-well plates
and one day later were treated with different compounds
at concentrations ranging from 10 to 1,000 nM (uran-
tide, UII, UPG83 and UPG85) or with concentrations
ranging from 10 to 2,000 nM (UPG84). Cell proliferation
was evaluated by MTT assay [19].Western blot analysis
Total proteins were prepared as described [19]. Membranes
were incubated with the following primary antibodies: (a)
anti-UTR; (b) anti- α-tubulin. Bound antibodies were de-
tected by horseradish peroxidase-conjugated secondary
antibodies, followed by enhanced chemiluminescence [19].expression and shorter time of relapse. B) Association between tumor
ted to low UTR expression also in the low grade carcinoma group.
Figure 5 Real time UTR mRNA quantification in bladder samples. LNCaP: calibrator; S: superficial bladder tumors; Inf: invasive bladder tumor.
Data were expressed as mean ± standard deviation (SD, n = 3).
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For determination of cell surface UTR expression,
analysis was performed using indirect UTR staining at
FACS. We have seeded and treated or not cells with
10 nM urantide or UPG84 for 72 h. After treatment,
cells were centrifuged and 4% paraformaldehyde was
added for 15 min at 4°C in the dark. Cells were incubated
in PBS/BSA for 10 min at 4°C and subsequently with
a primary rabbit polyclonal antibody raised against
human UTR (GPR14) or with an irrelevant immuno-
globulin (IgG1) or in PBS and processed as previously
described [19].Figure 6 Expression of UTR by Western blotting. Cell lines of
human bladder cancer are MCR, RT112, T24 and HT1376. The
housekeeping protein α-tubulin was used as loading control. Bars,
SDs. The experiments were performed at least three different times
and the results were always similar.Invasion and motility assays
For invasion assays, 8 μm inserts (Falcon) were employed
and Matrigel TM (Sigma) was diluted in serum-free
medium. Subsequently, assays were performed as previ-
ously reported [20].
Results
UTR expression was higher in NMIBC
We have evaluated UTR expression on a progressive
bladder TMA. We have found a mean expression of
UTR of about 16.67% and 13.57% for NMIBC and MIBC,
respectively. Percentage of negative cases was significantly
higher in MIBC than NMIBC. Pearson chi-squared test
showed significant higher UTR expression in NMIBC
(p = 0.0001) (Figure 1). These results suggest a higher
expression of UTR in NMIBC.
UTR expression correlated with low risk of relapses in
NMIBCs.
Our series included 125 males and 34 females, 118
(74%) older than 60 years of age (mean age 68, range
from 40 to 88 years). The anatomic sites of the tumour
were lateral wall in 87 cases (55%), cupola in 13 cases
(8%), trigon in 51 cases (32%). Relapses have been re-
corded in 75 patients (47%), from 1 (57) to 6 (1) total
episodes (Table 1).
High-grade primitive tumours have been observed in 41
patients (26%); the relapse tumor grade was the same of
primitive tumors in 71 cases (94%), while 4 cases (6%) of
the relapsed tumours showed higher grade than the
primary. In 53 cases (33%) lamina propria infiltration
was observed (Table 1).
High expression was recorded when positive cells
were > 30%. Patients with low expression of UTR were
94 (59%), in particular 38 (40%) without recurrences and
56 (60%) with histologically documented recurrences.
Moreover, 65 patients (41%) showed high expression of
UTR, 46 (71%) without recurrences and 19 (29%) with
Figure 7 Effects of agonist (UII), antagonist (Urantide, UPG83 and UPG85) and superagonist (UPG84) on bladder cancer cell growth. T24 (A),
RT112 (B) MCR (C) and HT1376 (D) cells were treated with UII, urantide, UPG83, UPG85 at concentrations ranging from 10 to 1,000 nM, and with UPG84 at
concentrations ranging from 10 to 2,000 nM (E), for 72 h at 37°C as described in “Methods” section.% of cell growth was calculated respect untreated cells
at 72 h from the beginning of the treatment. Same doses were used for the treatment at 48 h but in these cell lines, the 50% inhibition of cell growth was
achieved only at high concentration (T24) or was not reached (RT112). Asterisks indicate the statistical significance of the data (P <0.005). (F) HT-1376 (grey)
and T24 cells (black) were cultured in the presence or absence of either 10 nM urantide or UPG84 and the expression of UTR was evaluated at FACS at 48
and 72 h as reported in “Methods”. The intensity of UTR expression was represented as% Mean fluorescence intensity (MFI) calculated comparing the MFI
of cells incubated with the compounds with those of not treated cells. Each value is the mean of at least three different determinations performed in three
different experiments. Bars, SEs. The experiments were performed at least three different times and the results were always similar.
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sociated to low grade carcinoma (p = 0.044) while low
expression was associated to cases that have developed
at least one relapse (p = 0.001). Moreover, UTR expres-
sion in relapses was significantly lost respect to primary
tumors (p = 0.025) (Figures 2 and 3).
The decrease of the correlation between high UTR
expression and absence of relapse was likely due to
the short time of observation that could explain theTable 2 IC:50s at 72 h of different UTR agonists and
antagonists on bladder cancer cell lines
Cell lines Compounds IC:50 (nM)
UII Urantide UPG83 UPG85 UPG84
T24 n.d. 350 ± 8 n.d. n.d. 7 ± 0,6
RT112 n.d. 375 ± 6 n.d. n.d. n.d.
MCR n.d. n.d n.d. n.d. 9,8 ± 0,5
HT1376 n.d. n.d. 1000 ± 9 n.d. 7,9 ± 0,4
n.d.: not detectable; IC:50: drug concentration that induces the 50% of cell growth
inhibition after 72 h from the beginning of the treatment; UII: urotensin II.presence of some patients who will develop the relapse in
the following observation time (likely expressing low
UTR levels).UTR expression was directly correlated with DFS
Considering only first relapse, we recorded a significant
association between low UTR expression and shorter time
to relapse (p = 0.004). As expected tumor grade was asso-
ciated to recurrence (p = 0.02) (Figure 4). Also considering
low grade carcinoma group, shorter DFS was associated to
UTR low expression (p = 0.01) (Figure 4).
In a multivariate analysis including UTR expression
and grade, only UTR appeared to be an independent
prognostic factor (p = 0.025).UTR protein expression modulation was due to changes
in its mRNA levels in bTCC.
UTR gene expression was evaluated on LNCaP cell line and
14 NMIBC and 3 invasive MIBC samples by Real-Time
PCR quantification.
Figure 8 Effects of down-regulation or block of UTR with either an anti-UTR shRNA or the specific antagonist urantide on cell motility
and invasion of T24 cells. A: T24 parental (CTR) or transiently transfected with a shRNA for UTR (shUTR), were plated in the top chamber of
non-coated polyethylene teraphthalate (PET) membranes, treated or not with 100 nM urantide for 48 h and cell motility was evaluated as
described in Methods Section. B: For in vitro invasion assays, T24 cells were added to a Boyden chamber coated with Matrigel and cell invasion
was evaluated as described in Methods Section. The migrating and the invading cells were stained with 0.25% crystal violet for 10 min and
photographed under a microscope. C: The histogram shows the quantification of the migrating and invading cells measured with a spectrophotometer
as OD, and the results are expressed as a percentage as compared to untreated T24 parental cells. The experiments were performed three different
times and the results are the mean of the obtained values. Bars, SDs. CTR, untreated T24 cells; Sc, T24 cells transfected with scrambled vector and
cultured for 48 h; Sc + UR, T24 cells transfected with scrambled vector and exposed for 48 h to 100 nM urantide; shUTR, T24 cells transfected with shUTR
and cultured for 48 h; shUTR + UR, T24 cells transfected with shUTR and exposed to 100 nM urantide for 48 h. Asterisks indicate the statistical significance
of the data (P <0.005).
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samples the expression was low while in 3 samples the in-
crease of expression was moderate. The most part of
NMIBC showed a significant increase in UTR mRNA ex-
pression (Figure 5). UTR gene expression was very low in
all invasive bTCC selected (Figure 5). Moreover, UTR
mRNA levels correlated with the expression of the protein
in all examined cancer samples.
In vitro effects of UII, Urantide, and other agonist/
antagonist ligands (UPG85, UPG84 and UPG83) on
bladder cancer
In order to evaluate the involvement of UTR-dependent
signaling pathway on the growth of bladder cancer cells,
biological effects of human agonists (UII and UPG84),and antagonists (urantide, UPG83 and UPG85), were
evaluated on proliferation of human bladder cancer cell
lines MCR, RT112, T24 and HT1376 (Figure 6) after
72 h of treatment. UII had no significant effects on the
proliferation of all cell lines (Figure 7A-D). The 50%
growth inhibitory concentration (IC:50) of urantide was
350 nM in T24 and 375 nM in RT112 while it was not
achieved in HT1376 and MCR cells (Table 2). UPG84 in-
duced 45-50% growth inhibition at a concentration close
to the supposed Kd of UTR (about 10 nM) in all cell lines
with the exception of RT112 cells that were almost in-
sensitive (Figure 7E). Interestingly, UPG84 is a superago-
nist of UTR (Additional file 1: Table S1) and the addition
to cell culture for 72 h could affect UTR expression on cell
surface for internalization process triggering. On this light,
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induced a time-dependent down regulation of UTR
expression that reached an about 50% and 60% decrease at
72 h from the beginning of the treatment on HT-1376 and
T24 cells, respectively (Figure 7F). On the other hand,
urantide induced 30 and 20% decrease of UTR expression
in HT-1376 and T24 cells, respectively (Figure 7F).
Effects of Urantide and UTR knock-down on motility and
invasion of bladder cancer cells
In order to explore the specific contribution of UTR in
regulation of motility and invasion of bladder cancer
cells, T24 and RT112 cells were treated with urantide
(100 nM) for 48 h and/or were transiently transfected
with shRNA for UTR to down-regulate UTR protein ex-
pression. Cells were seeded in transwell chambers and
allowed to migrate and invade in absence or presence ofFigure 9 Effects of down-regulation or block of UTR with either an an
and invasion of RT112 cells. A: RT112 parental (CTR) or transiently transfe
of non-coated polyethylene teraphthalate (PET) membranes, treated or not
described in Methods Section. B: For in vitro invasion assays, RT112 cells were
evaluated as described in Methods Section. The migrating and the invading c
under a microscope. C: The histogram shows the quantification of the migrat
the results are expressed as a percentage as compared to untreated RT112 pa
the results are the mean of the obtained values. Bars, SDs. CTR, untreated RT1
for 48 h; Sc + UR, RT112 cells transfected with scrambled vector and exposed
and cultured for 48 h; shUTR + UR, RT112 cells transfected with shUTR and ex
significance of the data (P <0.005).urantide. After 48 h, urantide induced an about 35% and
50% reduction of cell motility and invasion, respectively, in
T24 cells if compared to untreated cells. When T24 cells
were transfected with shUTR displayed 45% and 56%
inhibition of their ability to migrate and invade, respectively
(Figure 8A and B, respectively). Downregulation of UTR in
T24 treated with urantide did not increase the effect in-
duced by urantide alone (Figure 8A and B, respectively).
Similar results were also obtained in RT112 (Figure 9A
and B). These data demonstrated that UTR is involved in
both motility and invasion of human bladder cancer cells.Discussion
NMIBC is characterized by a wide range of neoplastic
proliferation with a high propensity to recur and a not neg-
ligible tendency to progress to MIBC [21]. Currently, bothti-UTR shRNA or the specific antagonist urantide on cell motility
cted with a shRNA for UTR (shUTR), were plated in the top chamber
with 100 nM urantide for 48 h and cell motility was evaluated as
added to a Boyden chamber coated with Matrigel and cell invasion was
ells were stained with 0.25% crystal violet for 10 min and photographed
ing and invading cells measured with a spectrophotometer as OD, and
rental cells. The experiments were performed three different times and
12 cells; Sc, RT112 cells transfected with scrambled vector and cultured
for 48 h to 100 nM urantide; shUTR, RT112 cells transfected with shUTR
posed to 100 nM urantide for 48 h. Asterisks indicate the statistical
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most important predicting factors of progression in NMIBC
[22,23]. Interpretation of histopathologic criteria can also be
hampered by significant variability among pathologists [24].
On these bases, molecular markers predictive of progres-
sion in NMIBC are urgently needed. Identification of gene
expression profile of NMIBC helped to prognostic stratifica-
tion of patients, in order to recognize high-risk patients in
terms of tumor progression [25]. However, although exten-
sive efforts, no promising markers suggested by several
groups have yet been able to meet these criteria [26].
UII and its receptor are widely expressed and UII
represents a potent endogenous vasoconstrictor with
physiological mechanisms similar to other potent mediators
[27]. In literature, there are several evidences that associate
the altered expression of UTR in many cell lines and tumor
tissues [28,29].
In some cases it is described an up-regulation of
UTR/UII pathway, in others a down regulation correlated
to tumour progression [14,15]. In this light, we have previ-
ously demonstrated that UTR expression correlates with
good prognosis of prostate cancer and is able to discrimin-
ate patients with good from those with bad prognosis and
with Gleason grade more than 7 and we have also reported
that UTR is likely involved in the regulation of prostate
cancer cell motility and invasion [12].
On these bases, we have analysed UTR expression in
bTCC samples. In this manuscript, we clearly show that
UTR expression is able to discriminate between NMIBC
and MIBC and is an independent predictive marker of
relapse in NMIBC.
UTR mRNA expression on a selected group of bladder
cancers suggested that the regulation of UTR in bladder
cancers was dependent upon its mRNA levels.
We also investigated upon UTR biological role in
bladder cancer cell lines. We have assessed biological effects
of human agonist (UII), synthetic agonist (UPG84) and
antagonists (urantide, UPG83 and UPG85) on the prolifer-
ation of human bladder cancer cell lines. UII, UPG85 and
UPG83 had no significant effects on cell growth while
UTR antagonists urantide and superagonist UPG84 inhib-
ited cell growth. Interestingly, the latter was more potent
than urantide reaching an about 50% growth inhibition
after 72 h of treatment on 3 out of 4 cell lines examined at
a concentration near to the supposed Kd of UTR. This
effect could be ascribed to UTR downregulation induced
by the superagonist likely due to the induction of its
internalization and subsequent degradation.
Since UTR seems to be involved in the regulation
of intracellular Ca++ levels correlated with cell contraction
and cytoskeleton changes, we have evaluated effects of
shUTR and urantide on both motility and invasion of
RT112 and T24 cells [30,31]. Indeed, we found that down-
regulation of either the function or expression of UTRhad significant effects on both motility and invasion of
bladder cancer cells and that its down-regulation caused
by the specific shRNA induced biological effects similar to
those triggered by the addition of antagonist in T24 and
was even more potent in RT112.
Conclusions
We have studied the biological role of UTR in bladder
cancer and obtained data suggesting its involvement in
the regulation of cell motility and invasion. These data
suggest that UII/UTR mediated pathway may play a role
in bladder cancer progression. Finally, UTR expression
can be an independent predictive factor of progression
in NMIBC patients.
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